Form 4: Casdin Partners Boosts Stake in Standard BioTools

Casdin Partners Master Fund and related entities, including Director Eli Casdin, increased their beneficial ownership in Standard BioTools Inc. through recent stock purchases.

Summary

• Casdin Partners Master Fund, L.P. and affiliated entities purchased a total of 500,000 shares of Standard BioTools Inc. common stock.
• On September 3, 2025, 250,000 shares were acquired at a weighted average price of $1.2656 per share, with prices ranging from $1.2414 to $1.2765.
• On September 4, 2025, an additional 250,000 shares were acquired at a weighted average price of $1.2774 per share, with prices ranging from $1.2621 to $1.2930.
• Following these transactions, the indirect beneficial ownership of Casdin Partners Master Fund, L.P. increased to 60,775,000 shares.
• Eli Casdin directly owns 2,901,062 shares.
• Casdin Private Growth Equity Fund II, L.P. indirectly owns 13,939,637 shares.
• Casdin Private Growth Equity Fund, L.P. indirectly owns 2,744,219 shares.
• Eli Casdin, as managing member of Casdin Capital, LLC and Casdin Partners GP, LLC, is deemed to indirectly beneficially own shares held by the Master Fund and the Equity Funds.

Sentiment

Score: 8

Explanation: The significant insider buying by a major institutional investor and director indicates strong confidence in the company's valuation and future prospects, which is a positive signal for the market.

Positives

• Significant insider buying by a 10% owner and director, indicating confidence in the company's future prospects.
• The purchases occurred at prices ranging from $1.2414 to $1.2930, suggesting a belief in value at these levels.
• Increased alignment of interests between a major institutional investor/director and other shareholders.

Future Outlook

NA

Management Comments

• The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
• Eli Casdin has been deputized to represent the Reporting Persons on the board of directors of the Issuer.
• By virtue of Mr. Casdin's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the 'Exchange Act'), each of the Reporting Persons may be deemed directors by deputization of the Issuer.
• Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Industry Context

This filing reflects a significant investment by a major life sciences-focused fund in Standard BioTools, a company operating in the biotechnology and life sciences tools sector. Such insider purchases can signal confidence in the company's position within its competitive landscape, potentially indicating a belief in its technology or market strategy.

Corporate Governance

Related Party Transactions

• The reported purchases of common stock by Casdin Partners Master Fund, L.P. and related entities are considered related party transactions due to their status as 10% owners and directors (by deputization) of Standard BioTools Inc.

Stakeholder Impact

• Shareholders: The insider buying could instill greater confidence in the company's stock, potentially leading to positive sentiment and increased demand.
• Management: Reinforces alignment between a significant investor and the company's strategic direction.
• Employees: No direct impact mentioned, but positive investor sentiment can indirectly boost morale.

Key Dates

Recommendation

The substantial insider buying by a sophisticated institutional investor and director, Eli Casdin, signals strong conviction in Standard BioTools' valuation and future potential. Such a move by a well-informed party often precedes positive developments or indicates a belief that the stock is undervalued, making it a compelling 'buy' signal for other investors.

Keywords

Standard BioTools, LAB, Casdin Partners, Eli Casdin, Insider Buying, Form 4, Beneficial Ownership, Equity Purchase, Biotechnology, Life Sciences Tools